CD274 and gastroesophageal junction adenocarcinoma: Although SUG-CAP has demonstrated clinical efficacy in advanced G/GEJ adenocarcinoma with PD-L1 CPS ≥5, its cost is substantially higher than that of PLA-CAP, which inevitably increases medical expenses and imposes a heavy economic burden on patients and society.